Sources | Names Used |
---|---|
CTRPv2 | doxorubicin:navitoclax (2:1 mol/mol) |
PharmacoGx | doxorubicin:navitoclax (2:1 mol/mol) |
Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | SETD2 | CTRPv2 | pan-cancer | AAC | 0.17 | 8e-06 |
mRNA | BCL2L1 | CTRPv2 | pan-cancer | AAC | -0.16 | 8e-06 |
mRNA | PELP1 | CTRPv2 | pan-cancer | AAC | 0.15 | 8e-06 |
mRNA | NUDT3 | CTRPv2 | pan-cancer | AAC | 0.17 | 8e-06 |
mRNA | PRR3 | CTRPv2 | pan-cancer | AAC | 0.17 | 8e-06 |
mRNA | NME9 | CTRPv2 | pan-cancer | AAC | 0.14 | 8e-06 |
mRNA | KDM3B | CTRPv2 | pan-cancer | AAC | 0.15 | 8e-06 |
mRNA | R3HDM1 | CTRPv2 | pan-cancer | AAC | 0.16 | 8e-06 |
mRNA | RBM25 | CTRPv2 | pan-cancer | AAC | 0.15 | 8e-06 |
mRNA | BCOR | CTRPv2 | pan-cancer | AAC | 0.16 | 8e-06 |